News summary

Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation

Source: PR Newswire • Published: 18 Nov 2026, 21:05

Summarized by Masters of Longevity from PR Newswire.

Exaluren raised collagen IV and partially restored podocyte structure in three patients.

Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation
Key Takeaways
  • Exaluren increased COL4A3, COL4A4 and COL4A5 levels in biopsies.
  • Podocyte foot processes were partially improved after treatment.
  • Findings are from an open-label three-patient study and remain unproven.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickPlan Your Health Tests in Three MinutesThe free Personal Health Diagnostics Planner turns a short questionnaire into a ranked, personalised PDF: a clearer starting point for deciding which health checks deserve attention now.MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.